Eur Heart J:慢性阻塞性肺病患者血压和心率与死亡率的关系

2018-08-09 xing.T MedSci原创

COPD患者血压与全因死亡率以及心血管事件之间存在“U形”关系,并且心血管风险增加。心率与全因死亡率以及心血管事件之间存在线性关系,这些研究结果扩展了BP对不断增长的患者群体预后的重要性,并引起了对高血压和低血压可能造成健康风险的担忧。

近日,血管领域权威杂志Eur Heart J上发表了一篇研究文章,研究人员旨在明确慢性阻塞性肺病(COPD)患者血压(BP)或心率与死亡率和发病率之间的关系。

研究人员在SUMMIT试验中对基线血压或心率以及全因死亡率和血管事件进行了事后分析。SUMMIT试验是一项随机双盲结局试验,共有43个国家1368个地区的16485名参与者(65±8岁,75%男性和47%主动吸烟者)参加了该研究。患有中度COPD或有心血管疾病(CVD)风险的参与者被随机分配到安慰剂、长效β受体激动剂、吸入皮质类固醇或其组合治疗。

研究人员发现全因死亡率在相对较高的收缩压[≥140mmHg];风险比(HR)为1.27,95%置信区间(CI)为1.12-1.45]或舒张压(≥90mmHg; HR为1.35,95%CI为1.14-1.59)和较低的收缩压(<120mmHg; HR为1.36,95%CI为1.13-1.63)或舒张压(<80mmHg; HR为1.15,95%CI为1.00-1.32)的患者中升高。较高的心率(≥80次每分钟; HR为1.39,95%CI为1.21-1.60)和较大的脉压(≥80mmHg; HR为1.39,95%CI为1.07-1.80)与全因死亡率增加线性相关。心血管事件的风险与全因死亡率的模式相似。在没有明确CVD的患者亚组中也观察到了类似的结果。

由此可见,COPD患者血压与全因死亡率以及心血管事件之间存在“U形”关系,并且心血管风险增加。心率与全因死亡率以及心血管事件之间存在线性关系,这些研究结果扩展了BP对不断增长的患者群体预后的重要性,并引起了对高血压和低血压可能造成健康风险的担忧。

原始出处:

James Brian Byrd,et al. Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. Eur Heart J.2018. https://doi.org/10.1093/eurheartj/ehy451

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671895, encodeId=245716e18950b, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Mon Jan 28 07:40:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696839, encodeId=d3fd16968391f, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Nov 10 09:40:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356883, encodeId=d719135688364, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 11 09:40:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562952, encodeId=fb03156295266, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Aug 11 09:40:00 CST 2018, time=2018-08-11, status=1, ipAttribution=)]
    2019-01-28 amy0559
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671895, encodeId=245716e18950b, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Mon Jan 28 07:40:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696839, encodeId=d3fd16968391f, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Nov 10 09:40:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356883, encodeId=d719135688364, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 11 09:40:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562952, encodeId=fb03156295266, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Aug 11 09:40:00 CST 2018, time=2018-08-11, status=1, ipAttribution=)]
    2018-11-10 tomyang96
  3. [GetPortalCommentsPageByObjectIdResponse(id=1671895, encodeId=245716e18950b, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Mon Jan 28 07:40:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696839, encodeId=d3fd16968391f, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Nov 10 09:40:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356883, encodeId=d719135688364, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 11 09:40:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562952, encodeId=fb03156295266, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Aug 11 09:40:00 CST 2018, time=2018-08-11, status=1, ipAttribution=)]
    2018-08-11 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1671895, encodeId=245716e18950b, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Mon Jan 28 07:40:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696839, encodeId=d3fd16968391f, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Nov 10 09:40:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356883, encodeId=d719135688364, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 11 09:40:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562952, encodeId=fb03156295266, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Aug 11 09:40:00 CST 2018, time=2018-08-11, status=1, ipAttribution=)]
    2018-08-11 slcumt

相关资讯

Chest:COPD患者**端粒长度与生活质量、急性发作和死亡率之间的关系

由此可见,这些数据表明复制性衰老可能有助于预测COPD的不良预后。较短的白细胞端粒长度作为临床生物标志物可用于确定COPD临床结局较差风险增加的个体。

Eur Respir J:5-羟色胺能抗抑郁药的使用与老年COPD患者发病率和死亡率的关系

由此可见,刚开始使用5-羟色胺能抗抑郁药与COPD老年人呼吸相关发病率和死亡率小幅但显著增加有关。需要进一步的研究来澄清所观察到的相关性是否存在因果关系,还是未解决的混淆所致。

Radiology:间质改变对COPD患者的影响

本研究旨在验证是否胸部CT间接征象提示肺气肿对无肺纤维化改变的吸烟患者临床病变严重程度,将结果发表在radiology上。

Plerixafor可以预防与烟雾有关的COPD症状

近日研究表明,用于治疗某些癌症的药物也可以防止香烟烟雾引起的肺损伤。Plerixafor是一种刺激免疫系统的药物,可以将更多的干细胞(造血祖细胞或HPCs)从骨髓释放到血液中。

J Affect Disord:研究揭示COPD患者呼吸困难和抑郁症状之间的关系

抑郁症是COPD的常见合并症,COPD症状,如呼吸困难可能在COPD与抑郁之间的因果关系中起重要作用。本研究中,我们探究了COPD患者呼吸困难和其他COPD参数和抑郁症状之间的相互关系。研究共纳入了 590例COPD患者。在3周住院肺康复的开始(T0)和结束(T1),呼吸困难方面强度(BORG量表),频率(2个CCQ项目),功能(CCQ-功能)和认知/情绪反应(2 SGRQ)项目)以及咳嗽(2个C

BMJ:电话健康辅导可改善轻度COPD患者生活质量

研究发现,电话健康辅导不能改善轻度COPD患者的疾病症状,但可提高患者健康相关生活质量